
Zanamivir

产品编号: D51713

CAS: 139110-80-8

分子式: C₁₂H₂₀N₄O₇

纯度: ≥98%

InChi: InChI=1S/C₁₂H₂₀N₄O₇/c1-4(18)15-8-5(16-12(13)14)2-7(11(21)22)23-10(8)9(20)6(19)3-17/h2,5-6,8-10,17,19-20H,3H₂,1H₃,(H,15,18)(H,21,22)(H₄,13,14,16)/t5-,6+,8+,9+,10+/m0/s1

InChi Key: ARAIBEBZBOPLMB-UFGQHTETSA-N

Smiles: CC(=O)N[C@H]1[C@@H](OC(=C[C@@H]1N=C(N)N)C(O)=O)[C@H](O)[C@H](O)CO

外观: 固体粉末

作用通路: Antibiotic

溶解性: Soluble in DMSO, not in water

保存条件: Store in dry, dark place for one year.

产品介绍: Zanamivir is a neuraminidase inhibitor used in the treatment and prophylaxis of influenza caused by influenza A and B viruses. It was developed by the Australian biotech firm Biota Holdings. It was licensed to Glaxo in 1990 and approved in the US in 1999, only for use as a treatment for influenza. In 2006, it was approved for prevention of influenza A and B. Zanamivir was the first neuraminidase inhibitor commercially developed. Zanamivir works by binding to the active site of the neuraminidase protein, rendering the influenza virus unable to escape its host cell and infect others.[14] It is also an inhibitor of influenza virus replication in vitro and in vivo.